Evidence map›Paper›PMID 39020466›Full record

ArticleFEBS open bio2024

Design of an epitope-based peptide vaccine against Cryptococcus neoformans.

Ibtihal Omer, Isra Khalil, Ahmed Abdalmumin, Philisiwe Fortunate Molefe, Solima Sabeel, Islam Zainalabdin Abdalgadir Farh, Hanaa Abdalla Mohamed, Hajr Abdallha Elsharif, ALazza Abdalla Hassan Mohamed, Mawadda Abd-Elraheem Awad-Elkareem and 1 more

Abstract read
In one paragraph

Article in FEBS open bio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ibtihal OmerDepartment of Therapeutic Drug Monitoring Laboratory, National Center for Kidney Diseases and Surgery, Khartoum, Sudan.ORCID https://orcid.org/0000-0002-4431-3725
Isra KhalilDepartment of Microbiology, Faculty of Medical Laboratory Science, Sudan University of Science and Technology, Khartoum, Sudan.
Ahmed AbdalmuminBiomedical Research Institute, Sudan National University, Khartoum, Sudan.
Philisiwe Fortunate MolefeHair and Skin Research Laboratory, Department of Medicine, Division Dermatology, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
Solima SabeelDepartment of Pathology, Faculty of Health Sciences, Institute of Infectious Diseases and Molecular Medicine (IDM), University of Cape Town, South Africa.
Islam Zainalabdin Abdalgadir FarhFaculty of Dentistry, University of Khartoum, Sudan.
Hanaa Abdalla MohamedDepartment of Microbiology, Faculty of Medical Laboratory Science, Sudan University of Science and Technology, Khartoum, Sudan.
Hajr Abdallha ElsharifGeneral Administration of Quarantine and Animal Health, Regional Training Institute, Khartoum, Sudan.
ALazza Abdalla Hassan MohamedDepartment of Biotechnology, Faculty of Science and Technology, Omdurmam Islamic University, Sudan.
Mawadda Abd-Elraheem Awad-ElkareemDepartment of Biotechnology, Ahfad University for Women, Omdurman, Sudan.
Mohamed SalihDepartment of Biotechnology, Africa City of Technology, Khartoum, Sudan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cryptococcus neoformans is the highest-ranked fungal pathogen in the Fungal Priority Pathogens List (FPPL) released by the World Health Organization (WHO). In this study, through in silico simulations, a multi-epitope vaccine against Cryptococcus neoformans was developed using the mannoprotein antigen (MP88) as a vaccine candidate. Following the retrieval of the MP88 protein sequences, these were used to predict antigenic B-cell and T-cell epitopes via the bepipred tool and the artificial neural network, respectively. Conserved B-cell epitopes AYSTPA, AYSTPAS, PASSNCK, and DSAYPP were identified as the most promising B-cell epitopes. While YMAADQFCL, VSYEEWMNY, and FQQRYTGTF were identified as the best candidates for CD8+ T-cell epitopes; and YARLLSLNA, ISYGTAMAV, and INQTSYARL were identified as the most promising CD4+ T-cell epitopes. The vaccine construct was modeled along with adjuvant and peptide linkers and the expasy protparam tool was used to predict the physiochemical properties. According to this, the construct vaccine was predicted to be antigenic, nontoxic, nonallergenic, soluble, stable, hydrophilic, and thermostable. Furthermore, the three-dimensional structure was also used in docking analyses with Toll-like receptor (TLR4). Finally, the cDNA of vaccine was successfully cloned into the E. coli pET-28a (+) expression vector. The results presented here could contribute towards the design of an effective vaccine against Cryptococcus neoformans.

Indexed as

Cryptococcus neoformansEpitopes, B-LymphocyteEpitopes, T-LymphocyteFungal VaccinesVaccines, SubunitAmino Acid SequenceAntigens, FungalCryptococcosisHumansProtein Subunit VaccinesAntigens, FungalEpitopes, B-LymphocyteEpitopes, T-LymphocyteFungal VaccinesProtein Subunit VaccinesVaccines, SubunitCryptococcus neoformansepitopeglucuronoxylomannanin silicomannoproteinvaccine

Identifiers

PMID39020466
PMCPMC11492362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.